

# Phase I Study of MT1011 Injection in Healthy Subjects

NCT07024160

---

Status	RECRUITING
Phase	Phase 1
Sponsor	Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Enrollment	40 participants

## Key Eligibility Criteria

---

### Inclusion (4)

- Healthy male or female subjects (with at least 1/4 being either female or male), aged 18 to 45 years (inclusive) at screening;
- Body weight  $\geq$  50.0 kg for males and  $\geq$  45.0 kg for females at screening, with a Body Mass Index [BMI = weight (kg) / height<sup>2</sup> (m<sup>2</sup>)] within the range of 18.5 to 26.0 kg/m<sup>2</sup> (inclusive);
- Subjects must provide informed consent for this study prior to participation and voluntarily sign a written informed consent form;
- Subjects must be able to maintain good communication with the investigators.

### Exclusion (2)

- Subjects with abnormal and clinically significant findings in vital signs, physical examination, laboratory tests (blood routine, urinalysis, blood biochemistry, coagulation function), abdominal ultrasound, or chest X-ray as determined by the investigator;
- Women who are pregnant or breastfeeding, or female subjects with positive pregnancy tests; Subjects (or their partners) planning pregnancy, or planning to donate sperm/ova during the study or within

## Locations (1 total)

---

Beijing Shijitan Hospital, Capital Medical University, Beijing, Beijing Municipality, China